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The histone methyltransferase enhancer of Zeste
homolog 2 (EZH2) is a candidate oncogene due to
its prevalent overexpression in malignant diseases,
including late stage prostate and breast cancers.
The dependency of cancer cells on EZH2 activity is
also predicated by recurrent missense mutations
residing in the catalytic domain of EZH2 that have
been identified in subtypes of diffuse large B cell lym-
phoma, follicular lymphoma and melanoma. Herein,
we report the identification of a highly selective small
molecule inhibitor series of EZH2 and EZH1. These
compounds inhibit wild-type and mutant versions
of EZH2 with nanomolar potency, suppress global
histoneH3-lysine 27methylation, affect gene expres-
sion, and cause selective proliferation defects. These
compounds represent a structurally distinct EZH2 in-
hibitor chemotype for the exploration of the role of
Polycomb Repressive Complex 2-mediated H3K27
methylation in various biological contexts.
INTRODUCTION
Histone lysine methyltransferases (HKMTs; HMTs when referred
to both lysine and arginine methyltransferases) contribute to the
organization of chromatin structure, and thus play a role in the
regulation of gene expression. EZH2 and EZH1 catalyze methyl-
ation of histone H3 lysine 27 (H3K27) and function as part of a
multi-subunit complex termed Polycomb Repressive Complex
2 (PRC2) with well-documented roles in regulating cell identity
(Margueron and Reinberg, 2011). PRC2 is tightly linked to the
repression of transcription, whereby a variety of genes are
repressed in different cell types (Squazzo et al., 2006). Chro-
matin-bound PRC2 mediates transcriptional repression at least
in part by H3K27 methylation, although resultant chromatinChemistry & Biology 20, 1329–133architectural and mechanistic consequences are not fully under-
stood. Moreover, noncatalytic PRC2 functions that contribute to
transcriptional repression have also been described (Hansen
et al., 2008; Margueron et al., 2008; van der Vlag and Otte,
1999), and the context in which the PRC2 catalytic activity is
required to exert gene silencing remains to be determined. The
polycomb group (PcG) proteins SUZ12, EED, EZH2 or its homo-
log EZH1, RBBP4, and RBBP7 constitute the ‘‘core PRC2’’ while
accessory factors that further regulate PRC2 recruitment,
chromatin residency, and catalytic activity constitute the PRC2
holoenzyme (Margueron and Reinberg, 2011). Removal of core
subunits (Montgomery et al., 2005; Pasini et al., 2004) but not
accessory factors (Li et al., 2010; Pasini et al., 2010; Peng
et al., 2009) by genetic or RNAi-based approaches destabilizes
EZH2 and results in the abrogation of all PRC2 function.
EZH2 has been widely implicated in cancer progression,
largely due to its prevalent overexpression that correlates well
with significant increases in H3K27 methylation, disease stage,
and poor prognosis (Kleer et al., 2003; Varambally et al., 2002).
Despite the impressive disease association data, the extent to
which these cancers essentially depend on EZH2 is still unclear.
Even less understood is whether the EZH2 catalytic or noncata-
lytic functions dominate in a given disease context. The identifi-
cation of recurrent mutations within the EZH2 catalytic domain
provided powerful evidence that certain cancers might indeed
be dependent on the EZH2 catalytic activity. All identified
mutated residues Y641, A677, and A687 alter substrate speci-
ficity, facilitating the conversion from H3K27 dimethylated
(me2) to trimethylated (me3) states (Majer et al., 2012; McCabe
et al., 2012a; Sneeringer et al., 2010; Wigle et al., 2011; Yap
et al., 2011), while wild-type (WT) EZH2 preferentially converts
H3K27me1 to H3K27me2. With respect to lymphoma, EZH2
mutations are found exclusively in germinal center B cell-like
diffuse large B cell lymphoma (GCB-DLBCL) and follicular lym-
phoma (FL) but not in activated B cell DLBCL (ABC-DLBCL) or
any other subtype, suggesting that EZH2 dependence might
be restricted to certain lymphoma subtypes. Interestingly, these
cancers always select for one EZH2 mutant and one WT allele,
supporting the idea that both WT and mutant EZH2 are required.9, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1329
Table 1. Identification and improvement of EZH2 small molecule
inhibitors





























aData derived from >15 experiments ± SD
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Selective Lymphoma Cell Killing by EZH2 inhibitionRecently, EZH2 small molecule inhibitors have been disclosed
(Diaz et al., 2012; Knutson et al., 2012; Konze et al., 2013;
McCabe et al., 2012b; Qi et al., 2012). All identified compound
series are structurally related pyridones, arising from a common
or highly similar screening hit. The compounds demonstrated ef-
ficacy in EZH2 mutation-containing lymphoma cells, and thus
corroborate in this context an essential role for EZH2 to support
cancer cell growth. Herein we describe the identification and de
novo optimization of a structurally unrelated chemotype of small
molecule EZH2 inhibitor. High-throughput screening (HTS),
biochemical hit triage, and hit optimization led to the identifica-
tion of genuine, selective EZH2 inhibitors suitable to suppress
catalytic activity and alter EZH2-controlled gene expression pro-
grams in cell-based settings. Thus, these compounds can serve
as additional tools to investigate the disease contexts that
depend on the EZH2 catalytic function.
RESULTS
Hit Identification and Characterization
While of great biological interest, targeting enzymes that modu-
late histone methylation is an emerging field for drug discovery.
As such, there is a dearth of valid, well-characterized chemical
matter for HKMTs. In our experience, identification of potent,
valid methyltransferase inhibitors from screening campaigns is
a nontrivial exercise. Initial screening hits are typically of micro-
molar affinity, and thus require screening at high concentrations,
which introduces the need for significant downstream activities
to remove artifactual inhibitors (Diaz et al., 2012; Ferguson
et al., 2011; Francis et al., 2012; Kubicek et al., 2007). Given
this experience, we conducted a screening campaign utilizing
relatively high compound concentrations and a multistep triage1330 Chemistry & Biology 20, 1329–1339, November 21, 2013 ª2013process to identify all valid chemical matter regardless of
intrinsic potency.
A PRC2 enzymatic assay monitoring transfer of radioactive
methyl groups from the cofactor [3H]S-adenosyl-L-methionine
(SAM) to a biotinylated oligonucleosome substrate was em-
ployed (for details, see Figures S1A–S1C available online and
Experimental Procedures). Because no mode of biochemical
inhibition was considered inherently superior to others, assays
were run under balanced conditions with both SAM and oligonu-
cleosome concentrations at apparent Km (Kmapp, 200 nM each).
In this scenario, the likelihood of finding inhibitors of all three gen-
eral modes, competitive, noncompetitive, and uncompetitive, is
maximized (Copeland, 2003).
A total of 150,000 compounds from the unbiasedConstellation
compound collection were screened. Assays were run to 35%
substrate conversion using low nanomolar amounts of PRC2
with detection using streptavidin-coated Flashplates. Assays
were robust with S/B > 25 and Z0 of > 0.7. Specific hit cutoffs
depended on compound concentration (10–80 mM) and ranged
from 35% to 50%. Under these criteria, 288 confirmed hits
were identified and, as anticipated, the majority had weak
potency (> 20 mM). Therefore, hits were assessed using a multi-
stage process. First, frequent hitters, compounds with undesir-
able functionalities, and poor synthetic starting points were
removed. Next, hits were assessed in ten-point dose-response
curves where the steepness of the curves (as expressed by the
Hill coefficient) was monitored. Under standard assay condi-
tions, genuine inhibitors should have Hill coefficients of 1, while
those with undesired mechanisms of inhibition, e.g., covalent
modifiers, promiscuous aggregators, etc., generally have
steeper Hill coefficients (Shoichet, 2006). Only compounds
with Hill coefficients of 0.7–1.5 were considered. Selected com-
poundswere then assessed in three additional enzymatic assays
where titrations were run with (1) 10-fold enzyme, (2) 10-fold Km
SAM, or (3) 10-fold Km oligonucleosome substrate. These assays
allowed another check for nonideal behavior and to preliminarily
bin compounds based on potential mechanism of inhibition
(MOI). This MOI assessment was based whether they did or
did not shift in potency at cofactor and substrate concentrations
at 10-fold Km. According to the Cheng-Prusoff relationship
(Cheng and Prusoff, 1973) an increase in substrate above Km
should result in a predictable decreased inhibitor affinity for a
competitive compound, no effect for a noncompetitive com-
pound and enhanced affinity for an uncompetitive one.
After these analyses, several structurally distinct compounds
that met these criteria were identified. One of these, compound
1 (Table 1; Figure S1D) showed moderate potency, had a good
Hill coefficient, and shifted only with an increase in SAM, sug-
gesting aSAM-competitivemechanismof inhibition (Figure S1E).
Additionally 1 was found to be selective when assessed against
other HMTs in a biochemical assay (Figure S1F). Given these
properties and the potential for rapid modular synthesis of ana-
logs, this hit was selected for further optimization.
EZH2 Inhibitor Optimization
The aim of our initial medicinal chemistry campaign was to pros-
ecute and rapidly navigate the structure-activity landscape of the
tetramethylpiperidinyl-containing lead compound 1. Deriving
utility from amodular synthetic approach (Figure S1G), we swiftlyElsevier Ltd All rights reserved
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Selective Lymphoma Cell Killing by EZH2 inhibitionuncovered ligand efficient modifications of both the central ben-
zamide core and right-hand aryl group, which provided 2 with
sub-micromolar potency (Table 1; Figure S1H).
Because 2 had significantly better potency than the original
lead, more in-depth biochemical characterization was carried
out. Compound 2 inhibited WT EZH2 more potently than
Y641Nmutant EZH2 (Figure S1I) andmaintained the HMT selec-
tivity (Figure S1J) and SAM-competitiveMOI of the original lead 1
(Figure S1K). The cofactor-competitive mechanism of inhibition
also extended to the reaction product SAH where a Yonetani-
Theorell analysis indicated mutually exclusive binding (Fig-
ure S1L). Additional experiments were performed to rule out
inhibition by undesired or artifactual mechanisms. Specifically,
pre-incubation of 2 with EZH2 at high concentrations showed
no evidence of an irreversible mechanism of inhibition. However,
2 appeared fully reversible with complete restoration of activity
upon dilution (Figure S1M). The complex nature of the nucleo-
some substrates is such that DNA-intercalators can also appear
as artifactual inhibitors presumably by altering the substrate’s
architecture or enzyme binding (our unpublished results). To
rule this out, we developed an oligonucleosome-based interca-
lator assay and showed that 2 does not intercalate at concentra-
tions as high as 80 mM (Figure S1N).
Further investigation of the right-hand aryl group revealed that
substitution at the 3-position provided a significant improvement
in potency. The installation of a pyridazine in the 3-position
yielded compound 3 (Table 1) that exhibited significant in vitro
inhibition of PRC2with EZH2wt (half-maximal inhibitory concen-
tration [IC50] = 32 nM; Table 1, entry 3), EZH2 Y641N mutant
(IC50 = 197 nM) and EZH1 (IC50 = 213 nM; Figure 1A). Compound
3 remained SAM-competitive (Figure 1B) and retained excellent
selectivity (Figure 1C) as observed for other examples in this
series.
EZH2 Inhibitors Selectively Suppress Global H3K27
Methylation
Next, we sought to explore the compound’s ability to inhibit the
PRC2 HKMT activity in a cell-based setting. Compound 3
reduced bulk H3K27me3 and H3K27me2 levels in a dose-
dependent manner, while H3K27me1 levels were not affected
(Figure 1D). Other histone trimethylation marks, including
H3K4me3, H3K9me3, and H3K36me3, were not affected at
any of the tested concentrations, as expected based on the
biochemical selectivity. Importantly, the compound reduced
H3K27me3 without affecting EZH2, EZH1, SUZ12, and EED pro-
tein levels (Figure 1D). EZH2 and EZH1 inhibition significantly
reduced H3K27me3 levels in all cells within a given population,
albeit to different degrees (Figure 2A). Variability from cell to
cell in default H3K27me3 levels was observed in untreated cells
and this heterogeneity was maintained upon treatment (Fig-
ure 2B). Quantification of the average histone methylation signal
intensities confirmed that the compound 3 reduced H3K27me3
but not H3K4me3 and H3K9me2 in a dose-dependent manner
without significantly affecting cell viability (Figures S2A–S2E).
To determine cellular half-maximal effective concentration
(EC50), we used an ELISA-based technology. Compound 3 led
to efficient suppression of H3K27me3 in HeLa cells in a dose-
dependent manner with an approximate EC50 of 7 mM without
affecting cell viability to up to 30 mM (Figures 2C and 2D).Chemistry & Biology 20, 1329–133To study the effects of compounds within this series on the
histone modification landscape in an unbiased manner, we iso-
lated histones from HT and SUDHL6 GCB-DLBCL cells after
4 days of continuous treatment with compounds 1 and 3 and
measured the relative levels of 46 histone modifications (or com-
binations thereof) by mass spectrometry (Figure 3; Table S1). As
expected, the abundance of H3K27me3-containing histone pep-
tide species was clearly reduced in both cell lines by compound
3 but not by 1 due to its considerably weaker potency. The mass
spectrometry data were consistent with reduction of bulk
H3K27me3 in the same samples as observed by immuno-blot-
ting (Figures S2F and S2G). Default H3K27me3 levels were
significantly higher and H3K27me2 levels significantly lower in
mutant EZH2 (SUDHL6) compared to WT EZH2 (HT) cell lines,
consistent with the data from a previous study (Sneeringer
et al., 2010). Closer inspection of methylated H3K27 peptide
species abundance in HT and SUDHL6 cells showed a clear
reduction upon treatment with compound 3 but not with com-
pound 1 (Figure 3; Table S1). H3K27me3 peptide species were
most consistently affected in both cell lines while H3K27me2
abundance changed only modestly. Interestingly, compound
treatment led to different outcomes dependent on adjacent
modifications. Especially, H3K27me1 in the presence of
H3K36me2 (H3K27me1/K36me2) was consistently reduced in
both cell lines while H3K27me1/K36me0 was rather increased
in abundance. We also noticed a significant reduction in
H3K23me1 and histone H4 tri- and tetra-acetylation levels while
di- andmono-acetylation levels were unchanged (Figure 3; Table
S1). Notably, none of the other histone methylation marks were
changed in abundance upon compound treatment supporting
our earlier findings that 3 is highly selective for EZH2 and EZH1.
EZH2 Does Not Affect Growth of PC3 Prostate
Cancer Cells
EZH2 has been implicated in prostate cancer due to its signifi-
cant overexpression with concomitant increases in global
H3K27me3, which correlated with progression stage and prog-
nosis (Varambally et al., 2002). PC3 cells have been used previ-
ously as a model of advanced prostate cancer with EZH2 being
a prerequisite for metastasis formation in vivo (Min et al., 2010)
and increased cell growth, invasiveness, and morphology
changes in vitro (Bryant et al., 2007, 2008; Karanikolas et al.,
2010). Thus, we wanted to explore if this cell model is essentially
dependent on the EZH2 catalytic activity.
PC3 cells treated with compound 3 but not 1 exhibited a
significant reduction in global H3K27me3 levels after 4 and
10 days of treatment (Figure 4A), suggesting that EZH2 is
effectively engaged under these experimental conditions. How-
ever, we did not observe any effect on cell viability (Figure 4B) nor
did we observe a change to the transcript levels of reported
EZH2 target genes DAB2IP and SLIT1 (Figure 4C) over the
course of 10 days. To explore if the putative dependence on
EZH2 is due to noncatalytic PRC2 functions, we used an RNAi
approach. Two independent, nonoverlapping siRNA reagents
effectively reduced EZH2 transcript (Figure 4D, top) and protein
(Figure 4D, bottom) over the course of 10 days when compared
to a nontargeting siRNA control. Expectedly, EZH2 knockdown
resulted in significant reduction of global H3K27me3 levels
(Figure 4D, bottom). Surprisingly, we did not observe any PC39, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1331
Figure 1. Characterization of a Highly Selective EZH2 and EZH1 Small Molecule Inhibitor
(A) Determination of the inhibitory potential of compound 3 on PRC2 reconstituted with WT EZH2 (left), Y641Nmutant EZH2 (middle), andWT EZH1 (right). PRC2
IC50 values are determined from ten point dose response curves run in duplicate ± SEM.
(B) Determination of themechanism of action of compound 3. Activity assayswere carried out under balanced conditions with 2.5 or 25 nMPRC2 (13 enzyme and
103 enzyme, respectively), with oligonucleosomes (103 NUC) or SAM (103 SAM) in excess. The IC50 value in presence of 103 SAM shifts 8.3-fold. Data are
derived from ten point dose response curves run in duplicate ± SEM.
(C) The inhibitory potential of compound3was testedagainst apanel ofHKMTs, includingWHSC1,SETD7,DOT1L,EHMT2, andSETD8.No inhibitionwasdetected
to up to 80 mM. All enzyme assays were carried out under balanced conditions as ten point dose response curves run in duplicate ± SEM
(D) HeLa cells were treated with 3.75, 7.5, 15, or 30 mM of compound 3 for 6 days and whole cell extracts analyzed by western blotting for levels of EZH2, EZH1,
SUZ12, EED, H3K27me3, H3K27me2, H3K27me1, H3K4me3, H3K9me3, and H3K36me3. GAPDH and H4 levels served as loading controls.
See also Figure S1.
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Selective Lymphoma Cell Killing by EZH2 inhibitiongrowth defect under these conditions (Figure 4E) and we could
not detect DAB2IP gene expression changes (Figure 4F).
Similarly, DU145 prostate cancer cells were unaffected by
compound 3 treatment for 10 days (Figure S3A). Despite the
lack of a growth defect, compound 3 effectively engaged the
target in DU145 cells as measured by global reduction in
H3K27me3 levels (Figure S3B). We also determined that RNAi-
mediated knockdown of EZH2 reduced global H3K27me3 levels
but did not affect cell viability (Figures S3C and S3D). To rule out
that the lack of phenotypic responses in these prostate cancer
lines is due to the limited potency of our compounds, we also
used the published EZH2 inhibitor GSK-126 (McCabe et al.,
2012b). Both PC3 and DU145 cells were unaffected by contin-
uous GSK-126 treatment for up to 10 days (Figures S3E–S3H).
We conclude that PC3 and DU145 cells do not require EZH2
for continued growth in vitro although we cannot rule out that1332 Chemistry & Biology 20, 1329–1339, November 21, 2013 ª2013the siRNA-mediated reduction of EZH2 was not efficient enough
to cause a corresponding phenotype.
EZH2 Inhibition Selectively Affects Growth and Gene
Expression in GCB-DLBCL Models
The discovery of recurrent mutations of EZH2 in GCB-DLBCL
and FL suggest that these cancers have selected for and are
thus addicted to mutant EZH2 function. To test this hypothesis
and to understand the specificity of compound 3 in treating lym-
phoma, we assessed its effect on the viability of two GCB-
DLBCL cell lines, Pfeiffer (harboring the A677G EZH2 mutation)
and OCI-LY19 (WT EZH2). Neither compound 1 nor 3 caused
any significant growth defect within 4 days of treatment (Fig-
ure 5A). However, longer term treatment with compound 3 for
7, 10, and 14 days resulted in significant growth suppression
in Pfeiffer cells while OCI-LY19 cells remained completelyElsevier Ltd All rights reserved
Figure 2. Inhibition of EZH2 HMT Activity
Results in Global Reduction of H3K27me3
(A) HeLa cells were treated with DMSO or com-
pound 3 (30 mM) for 3 days, cells were fixed, per-
meabilized, and analyzed for H3K27me3 levels by
immunofluorescence microscopy (IFM). Counter-
staining with Hoechst dye was used to illustrate
similar cell numbers in both treatment groups.
(B) Distribution analysis of HeLa cells treated with
DMSO or 15 and 30 mM of compound 3 for 3 days
and analyzed for H3K27me3 levels by IFM. Each
peak represents the distribution of H3K27me3
intensity across the entire cell population. This
analysis is used to calculate the average
H3K27me3 intensity for each treatment group. For
further information, see also Figure S2.
(C and D) Determination of EC50 (C) and GI50
(D) values with respect to changes in global
H3K27me3 levels (using a Mesoscale ELISA
assay) and effects on viability (using a luminescent
viability cell assay). Data are represented as the
mean of three independent experiments ± SD.
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Selective Lymphoma Cell Killing by EZH2 inhibitioninsensitive (Figure 5A, bottom). In contrast, compound 1 did
not elicit any growth defect in OCI-LY19 and only marginally
affected growth in Pfeiffer at the highest dose even after
14 day treatments (Figure 5A, top). To ensure that we achieved
target coverage we determined global H3K27me3 levels in the
same samples. Compound 3 but not 1 effectively reduced
H3K27me3 (Figures 5B and S4). All these data support the claim
that compound 3 significantly reduces global H3K27me3 levels
in a dose-dependent manner irrespective of cellular context.
Compound 1 caused a reduction in H3K27me3 only at the high-
est doses, which is consistent with the fact that compound 1 is a
significantly weaker EZH2 inhibitor than compound 3.
EZH2 is implicated in transcriptional silencing, which is at
least partially mediated by the placement and maintenance of
H3K27me3. To better understand the impact of EZH2 inhibition
on gene regulation, we examined transcript levels of several pre-
viously identified EZH2-regulated genes in Pfeiffer cells. ABAT,
EPB41L1, APOL1, CEACAM1, PIGZ, SESN3, and SOX9 tran-
script levels were increased by compound 3 in a dose-depen-
dent manner (Figure 5C). We also explored the impact on genes
that are important for cell cycle progression and observed either
no significant change (as in the case of CDKN2A, CDKN1A, and
CDKN2B; Figures 5C and S5) or downregulation (for CDKN1C
and CDKN2D; Figure S5). These data are consistent with the
impact on gene regulation achieved by a structurally different
EZH2 inhibitor (McCabe et al., 2012b).
DISCUSSION
HKMTs represent an enzyme class of attractive drug targets,
many of which with proven or putative roles in cancer. The
PRC2 catalytic component EZH2 has been pursued by several
companies, and multiple closely related EZH2 small molecule
inhibitors have been disclosed. We have developed a PRC2Chemistry & Biology 20, 1329–1339, November 21, 2013 ªbiochemical assay in which we use oligo-
nucleosomes as substrate and ‘‘activate’’
PRC2 enzymatic activity by addingH3K27me3 peptides. This setup recapitulates a physiologically
relevant feature of the complex, the recognition of H3K27me3
by the EED subunit of PRC2, which was shown previously to
be relevant for H3K27 methylation in vivo (Margueron et al.,
2009). Through an HTS campaign and subsequent validation
of hits, we have identified a series of genuine chemical
matter that selectively inhibits wt and mutant EZH2 and EZH1.
These tetramethylpiperidinyl benzamide compounds represent
a EZH2 and EZH1 inhibitor chemotype that bears no structural
similarities with previously published HMT inhibitors.
Compounds 2 and 3 were approximately 10-fold weaker in
potency against PRC2 containing Y641 mutant EZH2 (Figures
1A and S1I). Because both biochemical assays were run at sub-
strate and cofactor Kmapps these differential effects are reflective
of the basal target affinities and subtle changes introduced by
mutation of Y641. Enzymological inspection indicated that
SAM and EZH2 inhibitor binding are mutually exclusive (Fig-
ure S1L). Thus, it is likely that compounds from this series directly
bind to the catalytic domain of EZH2. Moreover, a consistent
theme for this compound series was the approximately 10-fold
weaker inhibition of PRC2 harboring EZH1 (Figure 1A). However,
the series retained excellent enzymatic selectivity against other
HMT family members (Figure 1C).
When evaluated in a cellular context for the global reduction of
H3K27me3, 3 significantly shifted in potency. This disparity
between the biochemical and cell potency can be attributed to
a combination of the poor permeability of 3 (Caco-2 Papp:
0.4 3 106 cm/s) and high endogenous SAM concentrations.
These observations are not dissimilar to those reported by other
groups (Knutson et al., 2012; McCabe et al., 2012b; Qi et al.,
2012) and are likely a common theme for inhibiting HMTs with
cofactor-competitive compounds because KM
SAM are often sub-
micromolar (EZH2 200 nM) and several orders of magnitude
below endogenous SAM concentrations (Bennett et al., 2009).2013 Elsevier Ltd All rights reserved 1333
Figure 3. Inhibition of EZH2 HKMT Activity Affects H3K27me3 Species to Various Degrees
LC-MS/MS was used to analyze histone modification levels in HT (A) and SUDHL6 (B) cells upon treatment with 5, 15, and 25 mM of compound 1 or compound 3
for 4 days. Each bar represents a distinct histone modification or combination thereof. The experiment was carried out in triplicate ± SD.
See also Figures S2F and S2G and Table S1.
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Selective Lymphoma Cell Killing by EZH2 inhibitionWe used liquid chromatography-tandem mass spectorscopy
(LC-MS/MS) among various methodologies to monitor com-
pound-mediated effects on H3K27 methylation levels (Figure 3).
The mass spectrometry data—consistent with the antibody-
based methods—confirmed that global H3K27me3 and
H3K27me2 were reduced upon treatment with compound 3 but
not with the weaker compound 1. The data also illustrated that
the majority of other histone modifications were unaffected by
3, thereby providing support for the exquisite selectivity in a
cellular environment. Apart from H3K27me3 and me2 some,
but not all, H3K27me1 histone peptide species were reduced,
suggesting that EZH2 does not control global H3K27me1 levels
but rather at specific genomic locations in defined contexts
(e.g., in the presence of neighboring modifications). The only his-
tone modifications that were consistently reduced in both cell
lines in a dose-dependent manner were H3K23me1 and H4 tri-
and tetra-acetylation. These changesmight hint on yet undiscov-
ered ‘‘chromatin crosstalk’’ that remains to be further explored. A1334 Chemistry & Biology 20, 1329–1339, November 21, 2013 ª2013functional connection betweenH3K27 andH3K36 trimethylation,
specifically a bidirectional antagonism, has been reported earlier
(Zhenget al., 2012). Uponcompound treatment,weobserved the
reduction of both H3K27me3 in isolation and in the presence of
H3K36methylation. However, over the course of the experiment,
we did not detect any gain in H3K36 methylation levels despite
significant reduction of H3K27me3. Thus, in the context of lym-
phoma cells, it does not seem that PRC2 activity blocks the
placement of H3K36 methylation. Alternatively, it is possible
that the physical presence of catalytically inhibited PRC2 com-
plex still prevents H3K36-specific HMTs from accessing their
target site, and thus explains why we do not see increases in
H3K36 methylation upon reduction of H3K27me3 and me2.
EZH2 is overexpressed in many different cancer types
including metastatic prostate cancer. It has been previously
reported that EZH2 controls the proliferation and morphology
of PC3 prostate cancer models and silences important tumor
suppressor genes (Bryant et al., 2007, 2008; Chen et al., 2005;Elsevier Ltd All rights reserved
Figure 4. Inhibition of EZH2 HKMT Activity Does Not Affect Growth of PC3 Prostate Cancer Cells
(A) PC3 cells were incubated with compound 1 and 3 (30 mM) for 4 and 10 days and H3K27me3 levels were assessed by western blot. Total H4 levels and GAPDH
served as loading controls.
(B) PC3 cell viability was assessed upon treatment with DMSOor compound 1 and 3 (30 mM) for 4, 7, and 10 days using a luminescent cell viability assay. Shown is
one representative of three experiments.
(C) Expression level of the known EZH2 target genes, DAB2IP and SLIT2, were assessed upon treatment with DMSO or compound 1 and 3 (30 mM) for 1, 2, 4, 7,
and 10 days. Relative expression levels were graphed as a change compared to the DMSO-treated sample at day 1. Data are represented as themean of triplicate
experiments ± SD.
(D) EZH2 transcript (upper) and protein levels (lower) were determined upon siRNA-mediated knockdown for 1, 2, 4, 7, and 10 days (for transcript) and 4, 7, and
10 days for protein. H3K27me3 levels were determined as well (lower). EZH2 transcript level data are represented as the mean of triplicate experiments ± SD.
GAPDH served as a loading control.
(E) PC3 cell viability was assessed upon siRNA-mediated knockdown of EZH2 for 4, 7, and 10 days using a luminescent cell viability assay. Shown is one
representative of three experiments.
(F) DAB2IP transcript levels were assessed upon siRNA-mediated knockdown of EZH2 for 1, 2, 4, 7, and 10 days. Relative expression levels were graphed as a
relative change in comparison to nontargeting siRNA control (siNTC) at day 1. Data are represented as the mean of triplicate experiments ± SD.
See also Figure S3 and Table S3.
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Selective Lymphoma Cell Killing by EZH2 inhibitionKaranikolas et al., 2010; Yu et al., 2010). Surprisingly, we found
no evidence that the PRC2 H3K27-methyltransferase activity is
required for growth of the PC3 and DU145 prostate cancer cell
lines, and PRC2 inhibition did not affect the expression of the
DAB2IP and SLIT2 tumor suppressor genes. It remained a pos-
sibility that these prostate cancer cells depend on noncatalytic
PRC2 function. Moreover, it has recently been suggested that
EZH2 might function independently of its PRC2 components to
promote advanced prostate cancer growth (Xu et al., 2012).
We used two nonoverlapping siRNA sequences both of which
effectively reduced EZH2 transcript and protein levels and global
H3K27me3. However, we found no evidence that EZH2 level
reduction by RNAi over the course of 10 days impaired PC3
and DU145 cell growth or affected DAB2IP expression (Figures
4D–4F). Thus, it seemed that the requirement for EZH2 in pros-
tate cancer depends on a cellular context that is not recapitu-
lated by PC3 and DU145 cells.Chemistry & Biology 20, 1329–133On the contrary, the EZH2 inhibitor treatment resulted in
effective cell killing of Pfeiffer cells consistent with the effects
observed with other EZH2 inhibitors (Knutson et al., 2012;
McCabe et al., 2012b). Another GCB-DLBCL cell line, OCI-
LY19, was not sensitive to 3 despite continuous treatment for
14 days. Importantly, the difference in sensitivity was not due
to different levels of target engagement because we observed
potent suppression of global H3K27me3 in both cell lines (Fig-
ure 5B, lower panel). The data are consistent with the claims
that cell lines harboring EZH2 mutations (e.g., Pfeiffer) might
depend on PRC2 catalytic activity (Knutson et al., 2012; McCabe
et al., 2012b; Qi et al., 2012). Clearly, compound 3 treatment
does not result in general cytotoxicity because several cell
lines including HeLa, PC3, DU145, and OCI-LY19 were unaf-
fected with respect to growth despite the fact that all cell lines
exhibited strong reduction in global H3K27me3 levels. Impor-
tantly, we found that the timing of phenotypic consequences of9, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1335
Figure 5. GCB-DLBCL Cells Are Selectively Growth Inhibited and Gene Expression Is Altered upon EZH2 Inhibition
(A) GCB-DLBCL cell viability was assessed in response to compound treatment. Pfeiffer (left) and OCI-LY19 (right) cells were treated with compound 1 (top) or
compound 3 (bottom) for 4, 7, 10, and 14 days and viability was determined at each dose by luminescent cell viability assays. Experiments were carried out in
triplicate ± SD.
(B) H3K27me3 levels were assessed in Pfeiffer (left) and OCI-LY19 (right) cells upon treatment with compounds 1 (top) or 3 (bottom). H3K27me3 levels were
normalized to total H3. Experiments were carried out in triplicate ± SD. For more information, see also Figure S4.
(C) Transcript levels of ABAT, EPB41L1, APOL1, CEACAM1, PIGZ, SOX9, SESN3, and CDKN2A were determined in Pfeiffer cells upon treatment with various
concentrations of compound 3. Experiments were carried out in triplicate ± SD. For further information, see also Figure S5 and Table S3.
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Selective Lymphoma Cell Killing by EZH2 inhibitioncompound treatment in sensitive cell lines is dictated by efficient
target coverage over time as determined by dose-dependent
reduction of global H3K27me3 levels in a quantitative manner
(Figure 5B). Along with selective phenotypic effects, we also
demonstrated compound-induced increases in gene expression
consistent with the transcriptional effects observed by other
EZH2 inhibitors.
Overall, we have identified an EZH2 inhibitor chemotype that is
important given that all previously identified EZH2 inhibitors
occupy a very similar chemical space. These compounds will
serve as additional tools for the community and our biological
data obtained with these compounds support a potential thera-
peutic application of EZH2 inhibitors in GCB-DLBCL cases
harboring monoallelic EZH2 mutations.
SIGNIFICANCE
Small molecule inhibitors of HKMTs are of increasing
interest for cancer therapeutic applications. Despite signif-1336 Chemistry & Biology 20, 1329–1339, November 21, 2013 ª2013icant efforts, the community has generated potent, selec-
tive, and well-characterized inhibitors for only a small
number of HKMTs. Among these are inhibitors of EZH2,
all of which are of related chemotypes with similar proper-
ties. We have discovered a structurally distinct EZH2
inhibitor chemotype and improved the properties of these
compounds sufficiently to demonstrate biological effects
of EZH2 inhibition in a cellular setting. These effects
include reduction of global H3K27me3 and me2, but not
me1 levels and induction of gene expression. The com-
pounds affect the viability of a mutant EZH2-containing
GCB-DLBCL cell line but not of WT EZH2-containing
OCI-LY19 GCB-DLBCL and PC3 prostate cancer cells in
a dose- and time-dependent manner. Importantly, reduc-
tion of H3K27me3 was observed before measurable
phenotypic effects. This is consistent with the concept
that the timing of downstream functional consequences
of EZH2 inhibition is dictated by the efficient reduction of
H3K27me3.Elsevier Ltd All rights reserved
Chemistry & Biology
Selective Lymphoma Cell Killing by EZH2 inhibitionEXPERIMENTAL PROCEDURES
Biochemical Assays
PRC2 and biotinylated oligonucleosomeswere prepared in-house. H3K27me3
activator peptide (RKQLATKAARK(Me3)SAPATGGVKKP-NH2) was prepared
by custom synthesis (New England Peptide), SAH, and propidium iodide
were purchased from Sigma-Aldrich. [3H]SAM and streptavidin SPA plates
(FlashPlate) were purchased from Perkin-Elmer. All other reagents were of
reagent grade or better and purchased from commercial sources.
Radioactive assayswere read on a TopCount and fluorescence assays were
read on an Envision 2104 (both Perkin-Elmer) using filters and settings accord-
ing to manufacturers’ recommendations. Data were graphed and analyzed
with GraphPad Prism 5.0 (GraphPad Software) using curve-fitting analyses
appropriate to the experimental type.
PRC2 (WT or Y641Nmutant), biotinylated nucleosome, H3K27me3 activator
peptide and compound (in DMSO)were incubated in 50mMTris, pH 8.5, 5mM
MgCl2, 1 mM dithiothreitol (DTT), 70 mMBrij-35, and 0.1 mg/ml BSA for 30min.
Reaction was initiated by addition of [3H]SAM to final conditions of 5 nMPRC2,
200 nM nucleosome (concentration expressed as H3), activator peptide
(3.6 mM), and 200 nM [3H]SAM in a total volume of 25 ml in 384 well Greiner
plates. For compound analysis, assays were either single point or ten-point
dose responses with final total DMSO of 0.8 or 1.6% (v/v). Typically, assays
were run for 60 min with <35% substrate turnover. After reaction, assays
were quenched by addition of 20 ml of 2 mM SAH and 200 mM EDTA in
50 mM Tris, pH 8.5. Reactions were transferred to streptavidin-coated
FlashPlates, incubated for 2 hr, aspirated, washed, and read on a TopCount.
Cell Culture, Viability Assays, and Western Blotting
HT, OCI-LY19, SUDHL6, Pfeiffer, and PC3 cells were grown in Roswell Park
Memorial Institute (RPMI) GlutaMAX medium supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen). To assess
cell viability, cells were cultured for 3–4 days in a 96-well plate in the presence
of compound 1 or 3 and subsequently subjected to Cell Titer-Glo luminescent
cell viability assay (Promega) according to the manufacturer’s instructions. For
long-term assays, cells were passaged every 4 days (in a 1:4 to 1:5 ratio) into
fresh medium containing compound 1 and 3. GraphPad Prism 5 was used for
curve fitting.
For western blotting, nuclear extracts were prepared from HeLa, cells by
first separating the cytoplasmic fraction using buffer A (10 mM Tris [pH 7.9],
1.5 mM MgCl2, 10 mM KCl, 25 mM NaCl, 0.5 mM DTT, 0.2 mM phenylmetha-
nesulfonyl fluoride [PMSF], and protease inhibitors [Complete mini, Roche]).
The nuclear fraction was subsequently isolated using buffer B (25 mMHEPES,
1 M NaCl, 20% glycerol, 1.5 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 0.5 mM
PMSF, and protease inhibitors). For the HT and SUDHL6 cell extracts, a whole
cell lysate was prepared using RIPA buffer (50 mM Tris [pH 7.5], 1 M NaCl, 1%
NP-40, 0.5% sodiumdeoxycholate, 0.1% SDS, and protease inhibitors). All
antibodies are described in Table S2.
High Content Microscopy
HeLa cells (2,500/well) were treated with compound 3 for 72 hr then fixed with
4% paraformaldehyde. Cells were immunostained with primary antibodies
against specific histone marks and an antibody recognizing unmodified forms
of multiple histones (Table S2). After extensive washes, secondary antibodies
conjugated with Alexa Fluor 488 (Invitrogen #A11034, 1:500) or Alexa Fluor 594
(Invitrogen #A11032, 1:500) fluorescent dyes were used to label histone marks
and total histone, respectively. Hoechst 33342 fluorescent dye (Invitrogen
#H3570, 1:4,000) was used to depict DNA in nuclei. Immunofluorescent
imageswere acquired on a ImageXpressMicro (Molecular Devices) instrument
using appropriate filter sets. Images were processed and analyzed using the
built-in Multi Wavelength Cell Scoring application module. Average intensity
values were plotted in Spotfire.
Mesoscale ELISA Assays
HeLa cells were treated with compound 3 for 96 hr. After removal of media,
cells were rinsed with PBS and lysed with a hypotonic buffer (10 mM HEPES
[pH 7.9], 5 mM MgCl2, 0.25 M sucrose, Benzonase (1:10,000, Roche), 1%
Triton X-100 supplemented with 13 protease inhibitor cocktail [Roche] and
1 mM PMSF) followed by addition of NaCl to a final concentration of 1 M.Chemistry & Biology 20, 1329–133GCB-DLBCL cells were directly lysed in media with 33 lysis buffer. The
lysates were diluted with Tris buffer (20 mM Tris [pH 7.5], 1 mM EDTA,
1 mM EGTA, supplemented with 13 Protease Inhibitor cocktail and 1 mM
PMSF) to a final salt concentration of 100 mM NaCl and added to MULTI-
ARRAY microplates (L15XA-3, MSD) coated with anti-histone capture anti-
body that were previously blocked for 1 hr with 5% Blocker A solution
(R93AA-2, MSD). Following incubation, the lysates were discarded and the
plates were washed three times with Tris-buffer saline with 0.02% Tween-
20. H3K27me3 and H3 levels in the captured histones were detected using
adequate primary and secondary antibodies (Table S2) with a SECTOR
Imager 2400 instrument (MSD). GraphPad Prism 5 was used to calculate
EC50 values.
Quantification of Histone Modifications by Mass Spectrometry
HT, SUDHL6, and Pfeiffer cells were treated with up to 25 mM of compounds 1
and 3 for 5 days. Total histones were extracted from frozen cell pellets essen-
tially as described previously (Plazas-Mayorca et al., 2009). Briefly, nuclei iso-
lated from lysed cells were in 0.4N H2SO4, with acid-extracted histones
precipitated by TCA and acetone. The resulting pellets were redissolved in
HPLC-grade water and quantified by Bradford assay. Approximately 20 mg
of proteins were subsequently derivatized with proionic anhydride both prior
to and following trypsin digestion as described (Garcia et al., 2007). Derivat-
ized peptides were desalted using StageTips prepared in-house as described
(Rappsilber et al., 2007), and subsequently reconstituted in 2% acetonitrile
and 0.1% formic acid. Each sample was then loaded onto a PicoFrit nano-
bore column (75 mm ID) packed to the tip with 10 cm Magic C18AQ resin
(New Objective), at a rate of 300 nl/min on a NanoLC-1D+ pump (Eksigent
Technologies). Peptides were eluted on a 60 min gradient of 2%–35% aceto-
nitrile, supplemented with 0.1% formic acid. Each sample was analyzed three
times on an LTQ-Orbitrap XL mass spectrometer (ThermoFisher Scientific)
taking a full MS scan at a resolution of 30,000 in the Orbitrap and three
data-dependent MS/MS spectra in the ion trap. Histone H3 and H4 peptides
with various combinations of methylation and acetylation marks were identi-
fied and quantified in a semi-automated fashion following the mixed integer
linear optimization framework as previously described (DiMaggio et al.,
2009). To help account for run-to-run variability, the relative abundance of
each histone peptide was normalized to the sum of all modified and unmod-
ified forms of the same peptide as described previously (Plazas-Mayorca
et al., 2009).
Gene Expression Studies
Total RNA was isolated from cells using TRIzol (Life Technologies) according
to the manufacturer’s instructions. Generation of cDNA from 1 to 5 mg of total
RNA was performed using Random Primers (Life Technologies) and the
SuperScript III cDNA Synthesis Kit (Life Technologies). Diluted cDNA served
as input for qPCR reactions using FastStart Universal Probe Master (ROX)
and Universal Probe library (UPL) probes (Roche). A list of oligonucleotides
and UPL probes is provided in Table S3.
RNAi Experiments
SiRNAs against EZH2 were purchased from Life Technologies. For the exper-
iments in PC3 cells, reverse transfections were carried out using a final con-
centration of 5 nM siRNA. Cells were collected at defined time points after
transfection and used to determine cell viability (CTG; Promega), and knock-
down efficiency (RT-qPCR, western blot).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.09.013.
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